NVasc

NVasc, Inc. is an early-stage ophthalmology company founded in February 2019. The company focuses on treating the leading causes of blindness through choroidal and retinal vascular reconstruction. NVasc has acquired the research rights to growth factors (NVB001 and NVB002), which have been shown to promote the growth of non-leaky new blood vessels in the retina and choroid of mouse models with ischemic eye diseases. The company plans to produce NVB001 for use in toxicokinetic studies and early-phase human clinical trials.